These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 20881176)

  • 1. Hepatitis B virus (HBV) subgenotypes C2 and B2 differ in lamivudine- and adefovir-resistance-associated mutational patterns in HBV-infected Chinese patients.
    Li X; Wang L; Zhong Y; Wong VW; Xu Z; Liu Y; Li Q; Xin S; Zhao J; Xu D
    J Clin Microbiol; 2010 Dec; 48(12):4363-9. PubMed ID: 20881176
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of lamivudine-resistant mutational patterns with the antiviral effect of adefovir in patients with chronic hepatitis B.
    Cha CK; Kwon HC; Cheong JY; Cho SW; Hong SP; Kim SO; Yoo WD
    J Med Virol; 2009 Mar; 81(3):417-24. PubMed ID: 19152409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute hepatitis B infection associated with drug-resistant hepatitis B virus.
    Xu Z; Liu Y; Xu T; Chen L; Si L; Wang Y; Ren X; Zhong Y; Zhao J; Xu D
    J Clin Virol; 2010 Aug; 48(4):270-4. PubMed ID: 20580309
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigation into drug-resistant mutations of HBV from 845 nucleoside/nucleotide analogue-naive Chinese patients with chronic HBV infection.
    Li X; Liu Y; Zhao P; Wang Y; Chen L; Xin S; Zhang XX; Xu D
    Antivir Ther; 2015; 20(2):141-7. PubMed ID: 24992206
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Profile of HBV antiviral resistance mutations with distinct evolutionary pathways against nucleoside/nucleotide analogue treatment among Chinese chronic hepatitis B patients.
    Yang JX; Liu BM; Li XG; Yan CH; Xu J; Sun XW; Wang YH; Jiao XJ; Yan L; Dong JP; Hou CS; Abuduheilili X; Li T; Zhuang H
    Antivir Ther; 2010; 15(8):1171-8. PubMed ID: 21149924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High frequency of complex mutational patterns in lamivudine resistant hepatitis B virus isolates.
    Neumann-Fraune M; Beggel B; Pfister H; Kaiser R; Verheyen J
    J Med Virol; 2013 May; 85(5):775-9. PubMed ID: 23408582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.
    Lada O; Benhamou Y; Cahour A; Katlama C; Poynard T; Thibault V
    Antivir Ther; 2004 Jun; 9(3):353-63. PubMed ID: 15259898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of hepatitis B virus genotypes/subgenotypes in 1,301 patients with chronic hepatitis B in North China.
    Li XD; Wang L; Liu Y; Xu ZH; Dai JZ; Li L; Yao ZT; Xin SJ; Zhao JM; Xu DP
    Chin Med J (Engl); 2011 Dec; 124(24):4178-83. PubMed ID: 22340383
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence and types of drug-resistant variants in Chinese patients with acute hepatitis B.
    Su F; Dai J; Yang S; Jiang X; Cui X; Ning H; Li J; Huang M
    J Med Virol; 2015 Sep; 87(9):1527-31. PubMed ID: 26032700
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Detection Rate and Mutational Pattern of Drug-Resistant Mutations Between a Large Cohort of Genotype B and Genotype C Hepatitis B Virus-Infected Patients in North China.
    Li X; Liu Y; Xin S; Ji D; You S; Hu J; Zhao J; Wu J; Liao H; Zhang XX; Xu D
    Microb Drug Resist; 2017 Jun; 23(4):516-522. PubMed ID: 27792585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Different mechanism of selection of adefovir-resistant mutant viruses during adefovir monotherapy in patients with lamivudine-resistant chronic hepatitis B.
    Cho YK; Cui XJ; Jeong SU; Song BC
    Antiviral Res; 2014 Dec; 112():8-17. PubMed ID: 25303802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients.
    Lampertico P; Viganò M; Manenti E; Iavarone M; Sablon E; Colombo M
    Gastroenterology; 2007 Nov; 133(5):1445-51. PubMed ID: 17983801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis B virus rtA181T/sW172non-stop mutation may increase resistance fold to adefovir- and entecavir-resistant mutants compared to rtA181T/sW172* mutation.
    Zhao L; Li X; Cheng Y; Chen R; Shao J; Zhou Y; Li Q; Liao H; Zhao Y; Liu L; Su H; Liu Y; Liu Y; Xu D
    Antiviral Res; 2018 Jun; 154():26-34. PubMed ID: 29630974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Susceptibility of hepatitis B virus to lamivudine restored by resistance to adefovir.
    Zaaijer HL; Takkenberg RB; Weegink CJ; Rebers SP; Menting S; Reesink HW; Schinkel J; Molenkamp R
    J Med Virol; 2009 Mar; 81(3):413-6. PubMed ID: 19152408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of the rtI187V polymerase substitution of hepatitis B virus on viral replication and antiviral drug susceptibility.
    Fan J; Wang Y; Xiong H; Guo X; Cheng YC
    J Gen Virol; 2014 Nov; 95(Pt 11):2523-2530. PubMed ID: 25028473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Changes in viral loads of lamivudine-resistant mutants and evolution of HBV sequences during adefovir dipivoxil therapy.
    Suzuki F; Kumada H; Nakamura H
    J Med Virol; 2006 Aug; 78(8):1025-34. PubMed ID: 16789011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of HBV genotype, drug resistant mutations, and pre-core/basal core promoter mutations in Korean patients with acute hepatitis B.
    Lee JH; Hong SP; Jang ES; Park SJ; Hwang SG; Kang SK; Jeong SH
    J Med Virol; 2015 Jun; 87(6):993-8. PubMed ID: 25712861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Do different lamivudine-resistant hepatitis B genotypes carry the same risk of entecavir resistance?
    Lee GH; Aung MO; Dan YY; Lee YM; Mak B; Low HC; Lim K; Thwin MA; Tan PS; Lim SG
    J Med Virol; 2013 Jan; 85(1):26-33. PubMed ID: 23023992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevalence, virology and antiviral drugs susceptibility of hepatitis B virus rtN238H polymerase mutation from 1865 Chinese patients with chronic hepatitis B.
    Zhong Y; Lv J; Li J; Xing X; Zhu H; Su H; Chen L; Zhou X
    Antiviral Res; 2012 Jan; 93(1):185-90. PubMed ID: 22138714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence, viral replication efficiency and antiviral drug susceptibility of rtQ215 polymerase mutations within the hepatitis B virus genome.
    Amini-Bavil-Olyaee S; Herbers U; Mohebbi SR; Sabahi F; Zali MR; Luedde T; Trautwein C; Tacke F
    J Hepatol; 2009 Oct; 51(4):647-54. PubMed ID: 19586679
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.